Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE)

AMD Clinical Trial

— SINE  

Official title:

Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05547633
• Other study ID #: RLX-2022-4
• Status: Recruiting
• Start date: January 20, 2023
• Est. completion date: April 2026

Study information

• Verified date: January 2024
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: Amélie Yavchitz
• Phone: +33148036454
• Email: ayavchitz[@]for.paris
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

An inflammatory component associated with AMD has been highlighted by genetic associations of predisposition to AMD, as well as by the recently demonstrated link between AMD and periodontitis.

Some patients followed at the Fondation Adolphe de Rothschild Hospital for wet AMD seemed to show an improvement of neovascular activity (less need for intravitreal injections of anti-VEGF) after treatment of their sinusitis.

The investigators would therefore like to assess the link between AMD and sinusitis, an infection close to the site of AMD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: April 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Patient followed and treated for at least 2 years for bilateral neovascular form of age-related macular degeneration (AMD)

• At least one eye treated with = 6 intravitreal injections during the year preceding preinclusion

• Express consent to participate in the study

• Affiliated with or beneficiary of a social security plan

Exclusion Criteria:

• Persons referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curatorship).

• Severe myopia (> 6 diopters)

• Patient already being treated for acute or chronic sinusitis

• History of central serous chorioretinopathy or diffuse retinal epitheliopathy

Related Conditions & MeSH terms

• AMD
• Sinusitis

Intervention

Other:
• sinusitis screening consultation
Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy. Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary).

Locations

Country	Name	City	State
France	Hôpital Fondation A. de Rothschild	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Estimate the prevalence of sinusitis in patients with bilateral multi-injected neovascular AMD (= 6 intravitreal injections per year in at least one eye)	Percentage of patients with bilateral multiinjected neovascular AMD (=6 intravitreal injections/year in at least one eye) with sinusitis following ENT consultation screening.; Sinusitis is defined by nasofibroscopic abnormalities showing sinus pathology (inflammation, polyp, rhinorrhea) and/or scannographically confirmed sinus filling (some sinusitis is blocked and therefore not externalized).	Day 0
Secondary	To compare, between patients screened and managed for sinusitis and those not requiring treatment for sinusitis, the evolution of the number of intravitreal injections	Comparison of the change in the number of intravitreal injections performed over a 1-year period before sinusitis screening and then over a 1-year period after completion of sinusitis treatment (for patients treated for sinusitis) or a 1-year period after the screening visit for patients not treated for sinusitis.; If only one of the two eyes received 6 or more injections in the year before inclusion, the evolution of the number of injections for this eye will be considered. If both eyes received 6 or more injections in the year before inclusion, the eye with the most injections will be considered, if both eyes received the same number of injections the right eye will be considered by default.	Month 15